Document is current
Any future updates will be listed below
-
Authors
Cecchini, Michael
Kwiek, Bartlomiej
Liu-Walsh, Fang
Scully, Michael
Harakal, Jessica
Noss, Erika H.
Orillion, Ashley
Li, He
Gao, Bin
Tikhonov, Ilia
-
Funding
Funding for this research was provided by:
Johnson & Johnson
- License Information
-
More Information
Article History
Received: 14 January 2026
Accepted: 24 March 2026
First Online: 20 April 2026
Declarations
:
: Michael Cecchini is a medical dermatologist and was a principal investigator in this study. Bartlomiej Kwiek was a principal investigator in this study and reports serving as a clinical study investigator for AbbVie, Almirall, Amgen Inc, Arcutis Biotherapeutics, Aslan, Bristol Myers Squibb, Celdex Therapeutics, Celltrion, Dermira, Galderma, Glenmark, Incyte, LEO Pharma, Novartis, Pfizer, Regeneron, and Samsung. Fang Liu-Walsh, Michael Scully, Jessica Harakal, Erika H. Noss, Ashley Orillion, He Li, Bin Gao, and Ilia Tikhonov are employees of Johnson & Johnson and own shares or stock options of Johnson & Johnson.
: The study was approved by the institutional review board at each study site (complete list is provided in Table ). The study was conducted in accordance with International Council for Harmonisation Good Clinical Practice, the principles of the Declaration of Helsinki, and requirements of local ethics committees. All participants provided written informed consent.
